India's stringent drug regulations stifle innovative personalized therapies like gene editing, being ill-suited for individual patient needs. This bureaucratic hurdle, evident in Eroom’s Law, delays life-saving treatments. Countries like Germany and Australia demonstrate more flexible, physician-led approaches with informed consent. The author asserts India, possessing unique demographics benefiting from tailored cures, must courageously reform its regulatory framework. He advocates empowering physicians with clinical judgment and monitored trials, pooling lessons to advance patient care. Current guidelines are insufficient; freedom to apply science is crucial.